Why the Plateau Arrives

Ozempic launched in 2017. Semaglutide, the GLP-1 receptor agonist inside it, was developed across the preceding decade. The area postrema — a brain region near the base of your skull that houses some of the brain's appetite-regulating neurons — evolved over something closer to 500 million years. These are not evenly matched opponents.

When you inject semaglutide, it mimics glucagon-like peptide-1, a hormone your gut releases after eating. The drug travels to your brain, binds to GLP-1 receptors in the area postrema, and triggers a cascade of cyclic adenosine monophosphate (cAMP) — a molecular messenger that tells your neurons: you're full. The hunger signal gets intercepted. The pharmaceutical takes the wheel.

And then, for many people, somewhere between three and six months in: it stops working as well. The weight loss slows. The appetite creeps back. This is the plateau, and most explanations for it have pointed at metabolism — the body adjusting its calorie burn, finding equilibrium. That's real. But it's not the whole story.

New NIH research points directly at the neurons.

Specifically: some of them adapt. The cells that were responding to the drug — producing those sustained cAMP signals that told you to put the fork down — start internalizing and degrading their own GLP-1 receptors. Fewer surface receptors means less drug uptake means diminishing signal. Your neurons, faced with an exogenous compound hijacking their normal function, quietly removed the door the compound was walking through.

This is not a malfunction. This is the system working.

The adaptation isn't uniform — the NIH research found that cAMP responses "varied on a continuum" across individual neurons, which is why people plateau at different rates and to different degrees. Some neurons hold their response longer. Others downregulate quickly. The individual variation in drug response that doctors have observed clinically turns out to have a cellular explanation: it depends on which neurons you're working with, and how fast those particular neurons decide to stop cooperating.

The researchers also found a lever. An enzyme called PDE4 breaks down cAMP — it's essentially the cleanup crew that ends the signal. Block PDE4 with a drug called roflumilast, and more neurons shift toward sustained response. The cAMP signal persists longer. The plateau might be delayed or overcome.

Which raises the obvious observation: we are now discussing using a second drug to extend the effectiveness of the first drug, which was developed to manage the downstream effects of a food system engineered to override the natural satiety signals that evolution spent millions of years building. The pharmaceutical stack is acquiring layers.

There's no moral here about whether any of this is good or bad. GLP-1 drugs have genuinely helped people. Obesity causes devastating health effects. The plateau is a real clinical problem with real clinical stakes, and understanding its neurological mechanism is exactly what good science should do.

But it's worth pausing to note the scope of what we're attempting. Your area postrema didn't evolve to accommodate semaglutide. It evolved to help a primate survive famine by treating food as the most important variable in the environment. When you administer a GLP-1 agonist, you're not working with the system — you're rerouting it. And the system, being 500 million years old and relentlessly adaptive, starts rerouting back.

The plateau isn't failure. It's the ancient hardware filing a bug report.

i · sources

• Brain Cell Responses Explain Why GLP-1 Drugs May Lose Effectiveness — ScienceDaily, 2026-05-25